Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for October 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
AMA Announces Initiative to Reinvent Physician Training
TUESDAY, Oct. 30, 2018 (HealthDay News) — The American Medical Association (AMA) today announced a new $15 million competitive grant initiative, the “Reimagining Residency” initiative, aimed at improving residency training.
Community Health Worker Intervention Beneficial
TUESDAY, Oct. 30, 2018 (HealthDay News) — A standardized community health worker (CHW)-delivered intervention, Individual Management for Patient-Centered Targets, improves patient-perceived quality of care and reduces hospitalizations for low-income patients with chronic diseases, according to a study published online Oct. 22 in JAMA Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Many Hospitals Noncompliant With Record Request Regulations
MONDAY, Oct. 29, 2018 (HealthDay News) — Among top-ranked U.S. hospitals, data reveal discrepancies in information provided to patients regarding medical records release processes as well as noncompliance with state and federal regulations, according to a study published online Oct. 5 in JAMA Network Open.
Nurse-Led Care Efficacious, Cost-Effective for Gout
MONDAY, Oct. 29, 2018 (HealthDay News) — For patients with gout, nurse-led care is efficacious and cost-effective compared with usual care led by general practitioners (GPs), according to a study published Oct. 20 in The Lancet.
Trump Administration Announces Plan to Cut Drug Prices
FRIDAY, Oct. 26, 2018 (HealthDay News) — In an effort to cut high drug costs, the prices paid by Medicare for certain prescription drugs would be based on those in other advanced industrial nations, according to a proposal announced Oct. 25 by the Trump administration.
HHS Study
New York Times Article
Allopurinol Linked to Reduced Risk for CKD Stage ≥3 in Gout
THURSDAY, Oct. 25, 2018 (HealthDay News) — For patients with gout, allopurinol is associated with a reduced risk for developing chronic kidney disease stage ≥3, according to a study published online Oct. 8 in JAMA Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Pace of Change Has Accelerated in Alternative Payment Models
THURSDAY, Oct. 25, 2018 (HealthDay News) — The impact of alternative payment models (APMs) on physician practices has been described in a study published by the RAND Corp. and the American Medical Association.
Most Supplements Contain Prohibited Stimulants
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
Nearly Half of Adults With Arthritis Have Arthritis-Attributable Activity Limitations 
COPD Tied to Increased Risk for Death in Patients With Arthritis 
Overactive Bladder Positively Associated With Arthritis 
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease 
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder 
Exposure to Air Pollutants Linked to Increased RA Disease Activity 
Review Reveals Limited Effects of Exercise on Hip Osteoarthritis 
.jpg)